Biotec Pharmacon ASA announced that its Board of Directors has unanimously appointed Dr. Jethro Holter as the Company's interim Chief Executive Officer. Jethro, who currently serves as the Managing Director of ArcticZymes AS, a subsidiary of Biotec Pharmacon, will succeed Christian Jorgensen, the current CEO, effective immediately. Jethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a new strategic direction focusing the subsidiary's efforts towards growth, through expanding its B2B client base and implementing a customer-driven innovation approach for new product development. Consequently, the subsidiary has experienced strong revenue growth and vastly expanded its portfolio of novel enzyme products. Jethro has previous experience in international business development, R&D and sales from Life Technologies (Thermo Fisher Scientific), Mole Genetics AS, Pfizer Ltd. and other institutions.